Reviva Pharmaceuticals (RVPH) Projected to Post Quarterly Earnings on Monday

Reviva Pharmaceuticals (NASDAQ:RVPH) will likely be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.0543) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Reviva Pharmaceuticals Trading Down 4.0%

NASDAQ RVPH opened at $0.80 on Monday. The stock has a market capitalization of $5.15 million, a price-to-earnings ratio of -0.09 and a beta of 0.10. The business’s 50 day moving average is $4.88 and its two-hundred day moving average is $8.19. Reviva Pharmaceuticals has a 12-month low of $0.67 and a 12-month high of $23.40.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the first quarter worth $58,000. XTX Topco Ltd purchased a new position in shares of Reviva Pharmaceuticals in the second quarter valued at $31,000. Lido Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the 3rd quarter worth $37,000. State Street Corp raised its stake in shares of Reviva Pharmaceuticals by 202.4% during the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after buying an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares in the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on RVPH. Chardan Capital reaffirmed a “buy” rating and set a $40.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Finally, D. Boral Capital downgraded shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $66.67.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.